Secular trends in cytomegalovirus (CMV) risk and outcomes: results from a 10-year longitudinal cohort study in adult kidney transplant recipients

被引:0
|
作者
Perry, Amy [1 ]
Soliman, Karim [1 ,2 ,3 ]
Andrade, Erika [4 ]
Mesmar, Zaid [5 ]
Overstreet, Morgan [5 ]
Fulop, Tibor [1 ,2 ]
Calimlim, Isabel K. [5 ]
Harris, Courtney [6 ]
Taber, David J. [5 ,7 ]
机构
[1] Ralph H Johnson VA Med Ctr, Med Serv, 109 Bee St, Charleston, SC 29401 USA
[2] Med Univ South Carolina, Dept Med, Div Nephrol, Charleston, SC USA
[3] Med Univ South Carolina, Dept Surg, Div Transplant Surg, Charleston, SC USA
[4] Med Univ South Carolina, Coll Med, Charleston, SC USA
[5] Med Univ South Carolina, Dept Surg, Charleston, SC USA
[6] Med Univ South Carolina, Div Infect Dis, Charleston, SC USA
[7] Ralph H Johnson VA Med Ctr, Pharm Serv, Charleston, SC USA
关键词
Kidney transplantation; Follow-up studies; Longitudinal studies; Cytomegalovirus infections; Risk factors; Kidney; Opportunistic infections; CMV; Secular; Transplant;
D O I
10.1007/s11255-025-04399-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe goal of this study was to determine the secular trends in the incidence of CMV sero-mismatch (D+/R -) and if these trends meaningfully impact clinical outcomes.MethodsThis was a single-center longitudinal cohort study in adult kidney recipients transplanted between Jan 2012 and June 2021 with follow-up through June 2022. Baseline and follow-up data were collected. Univariate and multivariate statistics were used to analyze the data.Results2,392 kidney transplants were performed during the study period; 132 patients did not meet inclusion criteria. The mean age was 52 years, 41% were female, 57% were black, and 19% were CMV D + /R -. The odds of being CMV high-risk increased by 6% each year (OR 1.06, 1.02-1.10 p = 0.003); 48% of the variability associated with CMV serostatus was explained by transplant year (R2 = 0.478, p = 0.002). Sequential modeling demonstrated that CMV D + /R - serostatus was a substantial risk factor for CMV infection (HR 5.7, 4.5-7.3), CMV disease (HR 8.4, 3.9-18.0), CMV resistance (HR 17.9, 3.8-84.2), CMV refractory infection (HR 35, 4-280), late CMV infection (HR 12.0, 8.3-17.1), acute rejection, and hospitalization for opportunistic infections. Secular trend analysis demonstrated that CMV infections, CMV resistance, and late CMV increased in incidence since 2012. The risks of CMV resistance and late infection was significantly influenced by D + /R - serostatus and transplant year, indicating that this risk is worsening over time.ConclusionThe CMV D + /R - serostatus remains the single most important risk factor for CMV infection, disease, resistance, refractory infection, and late CMV, which appears to be increasing in magnitude.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Belatacept vs Cyclosporine in Kidney Transplant Recipients: Two-Year Outcomes from the BENEFIT Study
    Larsen, C. P.
    Grinyo, J.
    Charpentier, B.
    Pestana, J. Medina
    Kamar, N.
    Vanrenterghem, Y.
    Lin, C. -S.
    Di Russo, G.
    Garg, P.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 82 - 82
  • [42] Survival outcomes in uterine sarcomas - a 10-year retrospective cohort study from a tertiary centre
    Majd, Hooman Soleymani
    Aggarwal, Aakriti
    Zouridis, Andreas
    Pratap, Sarah
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A259 - A260
  • [43] Risk prediction of the metabolic syndrome using TyG Index and SNPs: a 10-year longitudinal prospective cohort study
    Kang, Sang Wook
    Kim, Su Kang
    Kim, Young Sik
    Park, Min-Su
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2023, 478 (01) : 39 - 45
  • [44] Risk prediction of the metabolic syndrome using TyG Index and SNPs: a 10-year longitudinal prospective cohort study
    Sang Wook Kang
    Su Kang Kim
    Young Sik Kim
    Min-Su Park
    Molecular and Cellular Biochemistry, 2023, 478 : 39 - 45
  • [45] MammaPrint 10-year follow up results from a German breast cancer cohort study
    Jackisch, C.
    Pronin, D.
    Dimpfl, T.
    Buttner, R.
    Kunz, G.
    Langwieder, C.
    Rees, M.
    Anzeneder, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S612 - S612
  • [46] Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study
    Douwes, Rianne M.
    Vinke, Joanna Sophia J.
    Gomes-Neto, Antonio W.
    Ayerdem, Gizem
    van Hassel, Gaston
    Berger, Stefan P.
    Touw, Daan J.
    Blokzijl, Hans
    Bakker, Stephan J. L.
    de Borst, Martin H.
    Eisenga, Michele F.
    TRANSPLANT INTERNATIONAL, 2021, 34 (11) : 2305 - 2316
  • [47] Assessment and Outcomes of Medication Nonadherence in Pediatric Kidney Transplant Recipients: Results from the IMPACT Study.
    Dokras, A.
    Pearl, M.
    Peipert, J.
    Grimm, P.
    Warshaw, B.
    Chambers, E.
    Kirk, A.
    Ettenger, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 338 - 339
  • [48] Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients
    Vincenti, F.
    Larsen, C. P.
    Alberu, J.
    Bresnahan, B.
    Garcia, V. D.
    Kothari, J.
    Lang, P.
    Mancilla Urrea, E.
    Massari, P.
    Mondragon-Ramirez, G.
    Reyes-Acevedo, R.
    Rice, K.
    Rostaing, L.
    Steinberg, S.
    Xing, J.
    Agarwal, M.
    Harler, M. B.
    Charpentier, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (01) : 210 - 217
  • [49] 12-year evolution of immunosuppressant non-adherence in adult kidney transplantation recipients: The Swiss Transplant Cohort Study
    Meury, P.
    De, Geest S.
    Denhaerynck, K.
    Dickenmann, M.
    Sturzinger, U.
    Huynh-Do, U.
    Binet, I
    Kunzler-Heule, P.
    Boehler, A.
    Beerli, N.
    Ribaut, J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01)
  • [50] Promising Results of Kidney Transplantation From Donors Following Euthanasia During 10-Year Follow-Up: A Nationwide Cohort Study
    Susanna, Charlotte
    van Dijk, Nathalie
    de Jongh, Wim
    Verberght, Hanne
    van Mook, Walther
    Bollen, Jan
    van Bussel, Bas
    TRANSPLANT INTERNATIONAL, 2024, 37